# OnCo record paper-scher-nuclear-arv7-taxane-vs-arsi-jama-oncol-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-scher-nuclear-arv7-taxane-vs-arsi-jama-oncol-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-scher-nuclear-arv7-taxane-vs-arsi-jama-oncol-2018" ;
  schema:name "Nuclear-localised androgen receptor splice variant 7 in circulating tumour cells as a predictive biomarker in castration-resistant prostate cancer"@en ;
  schema:description "A blinded three-hospital study found that men with the shortened receptor in their circulating tumour cells lived roughly twice as long on chemotherapy as on another hormone tablet, and that men without it did better the other way round."@en ;
  schema:url <https://onco.cc/key-papers/paper-scher-nuclear-arv7-taxane-vs-arsi-jama-oncol-2018/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2018.1621>, <https://pubmed.ncbi.nlm.nih.gov/29955787/> ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2018.1621> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Scher HI, Graf RP, Schreiber NA, et al." ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:pathways <https://onco.cc/pathways/ar-signaling/>, <https://onco.cc/pathways/rna-splicing/>, <https://onco.cc/pathways/intravasation-ctc-survival/> ;
  onco:terms <https://onco.cc/terms/ar-v7/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/resistance/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .